Brochure Available for the World Vaccine Congress

1 Event, 7 Conferences at the World Vaccine Congress 2015 The World Vaccine Congress is back for it’s 15th year on April 7-9 in Washington. With over 250 people already signed up to attend, ranging from pharma and biotech, to non-profits and governmental departments, it is set to be another great year. The event has grown for 2015. Not only …

Polio Strain Resistant to Vaccine was Responsible for 2010 Congo Outbreak

A vaccine resistant mutation of the poliovirus was the cause of the major 2010 polio outbreak in DR Congo Research published in the scientific journal ‘Proceedings of the National Academy of Sciences‘ has shown that a mutated strain of the poliovirus was responsible for a 2010 outbreak in the Democratic Republic of Congo, which claimed 209 lives. It was initially …

New Vaccine Provides Greater Protection than BCG Against Both Tuberculosis and Leprosy

Research headed by UCLA has found that a variation of the BCG vaccine offers stronger protection against the diseases Both tuberculosis and leprosy often occur together, and leprosy usually only occurs in places where tuberculosis occurs. Most infants are vaccinated against the two diseases with the Bacille Calmette-Guerin vaccination, which has been used for over a century now. However this …

Chikungunya vaccine candidate causes successful development of antibodies against the virus

Chikungunya Vaccine Candidate Passes Phase I Clinical Trials

Chikungunya vaccine candidate causes successful development of antibodies against the virus Chikungunya, a mosquito borne virus, has recently been responsible for outbreaks in the Caribbean and the Pacific. Although the disease is not usually fatal, it causes similar symptoms to a bad flu: muscle aches, malaise and headaches. However, one of the unique aspects of the virus is that it …

How do you bridge the gap between prophylactic and therapeutic vaccines?

How do you bridge the gap between prophylactic and therapeutic vaccines? "A vaccine that ‘treats' a disease before it causes morbidity would bridge the gap between prophylactics and therapeutics."But how? Download this presentation to discover more about bridging the gap between prophylactic and therapeutic vaccines including: · The next-best thing to prophylaxis · Therapy of still-healthy patients requires validated biomarkers …

Novel vaccine adjuvant for induction of cellular and humoral immunity

Dr Vincent Serra, Chief Executive Officer and Chief Scientific Officer, Wittycell  joined us at the World Vaccine Congress Lyon 2012 to discuss how Wittycell is developing novel vaccines and adjuvant products for both the therapeutic and prophylactic markets, with a focus on T cell response. Their Goal :OVA transfected cell line with OVA as antigen is a really good model …